MedTrace Logo

Efficacy of STABLOR® on Visceral Fat Mass Reduction in Patients With Metabolic Syndrome

NCT03692806 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2020-12-17

No results posted yet for this study

Summary

The primary objective of the study is to assess the efficacy of STABLOR® consumption on visceral fat mass compared to placebo, in persons with metabolic syndrome during 12 weeks of consumption.

Conditions

  • Metabolic Syndrome

Interventions

DIETARY_SUPPLEMENT

Stablor

Stablor sachet

DIETARY_SUPPLEMENT

placebo

placebo sachet

Sponsors & Collaborators

  • Biofortis Mérieux NutriSciences

    collaborator OTHER

  • StatistiCal BV Wassenarr, The Netherland represented by Dr W.Calame

    collaborator UNKNOWN

  • LNC THERAPEUTICS

    lead INDUSTRY

Principal Investigators

  • Marie Déciron, MD · BioFortis

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-09-11
Primary Completion
2019-10-31
Completion
2020-12-16

Countries

  • France
  • Ireland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03692806 on ClinicalTrials.gov